ICM Research

ICM Therapeutics is a clinical-stage biotechnology company pioneering the field of mitochondrial medicine to treat life-threatening diseases. The company's research focuses on the 'signaling logic' of the mitochondrial genome, specifically how mitochondria fragment and trigger oxidative stress under disease conditions. Their lead program, ICM-20, is a small molecule therapy currently advancing into Phase 2b clinical trials for the treatment of chronic Chagas cardiomyopathy, a leading cause of infectious heart failure. Beyond infectious diseases, ICM is leveraging its mitochondrial platform to develop a pipeline of therapies for oncology, heart failure, and metabolic disorders.